<DOC>
	<DOCNO>NCT01746992</DOCNO>
	<brief_summary>T cell lymphoma heterogenic malignancy poor outcome . Five-year PFS OS patient recieved classic CHOP regimen ( cyclophosphamide , vincristin , doxorubicin predisone ) less 30 % .High dose intensive chemotherapy ` demonstrate good response . At present , standardized treatment protocol kind lymphoma . Between 1994 1998 , Scotland Newcastle Lymphoma Group prospectively collect data newly diagnose patient enteropathy associate T-cell lymphoma ( EATL ) Northern Region England Scotland , rare aggressive type peripheral T-cell lymphoma.The novel regimen IVE/MTX ( ifosfamide , vincristine , etoposide/methotrexate ) -ASCT pilot patient eligible intensive treatment , follow auto-stem cell transplantation.Five-years PFS OS 52 % 60 % respectively , significantly improve compare historical group treat anthracycline-based chemotherapy . The encouraged result extend peripherial T cell lymphoma-non specify ( PTCL-nos ) . Past study suggest pirarubicin active T cell lymphoma doxorubicin vitro base high concentration tumor cell . Clinical data also present equivalent even superior efficacy pirarubicin low toxicity doxorubicin . The aim study compare response survival rate CTOP/ITE/MTX ( cyclophosphamide , vincristin , pirarubicin predisone/ ifosfamide , pirarubicin , etoposide/methotrexate ) CHOP regimen , look forward superiority efficacy safety de novo young patient T cell lymphoma .</brief_summary>
	<brief_title>CTOP/ITE/MTX Compared With CHOP First-line Therapy Newly Diagnosed Young Patients With T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
	<mesh_term>Panniculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>pathologic verified mature T cell lymphoma , include ALKnegative anaplastic large cell lymphoma , peripherial T cell lymphomanon specific type , angioimmunoblastic T cell lymphoma , enteropathy associate T cell lymphoma hepatosplenic T cell lymphoma SGOT/SGPT 2 time UNL serum creatinine 1.5 time UNL sign informed consent woman pregnancy lactation allergic intervention drug insuitable study due severe complication enrol study past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>